JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis

NASDAQ:JAZZ • IE00B4Q5ZN47

166.31 USD
+0.02 (+0.01%)
At close: Feb 13, 2026
166.31 USD
0 (0%)
After Hours: 2/13/2026, 8:18:31 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall JAZZ gets a fundamental rating of 4 out of 10. We evaluated JAZZ against 191 industry peers in the Pharmaceuticals industry. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation. JAZZ is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year JAZZ was profitable.
  • JAZZ had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
  • Each year in the past 5 years JAZZ had a positive operating cash flow.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • JAZZ has a Return On Assets of -3.24%. This is in the better half of the industry: JAZZ outperforms 74.35% of its industry peers.
  • Looking at the Return On Equity, with a value of -9.31%, JAZZ is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 3.95%, JAZZ belongs to the best of the industry, outperforming 82.72% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for JAZZ is significantly below the industry average of 12.64%.
  • The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(3.95%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROIC 3.95%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

  • In the last couple of years the Profit Margin of JAZZ has declined.
  • With an excellent Operating Margin value of 10.92%, JAZZ belongs to the best of the industry, outperforming 83.77% of the companies in the same industry.
  • In the last couple of years the Operating Margin of JAZZ has declined.
  • The Gross Margin of JAZZ (88.49%) is better than 90.58% of its industry peers.
  • In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 88.49%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • JAZZ has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
  • The debt/assets ratio for JAZZ is higher compared to a year ago.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 1.53, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.53, JAZZ perfoms like the industry average, outperforming 59.16% of the companies in the same industry.
  • JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 4.33, JAZZ belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.
  • JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.09, JAZZ is not doing good in the industry: 74.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Altman-Z 1.53
ROIC/WACC0.52
WACC7.58%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 1.65 indicates that JAZZ should not have too much problems paying its short term obligations.
  • The Current ratio of JAZZ (1.65) is worse than 68.06% of its industry peers.
  • A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.44, JAZZ is doing worse than 63.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.44
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.39%.
  • The Earnings Per Share has been growing slightly by 5.47% on average over the past years.
  • JAZZ shows a small growth in Revenue. In the last year, the Revenue has grown by 4.14%.
  • Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%

3.2 Future

  • JAZZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.62% yearly.
  • JAZZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.50% yearly.
EPS Next Y-60.74%
EPS Next 2Y4.5%
EPS Next 3Y6.57%
EPS Next 5Y8.62%
Revenue Next Year4.8%
Revenue Next 2Y5.63%
Revenue Next 3Y6.42%
Revenue Next 5Y7.5%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 20.38, JAZZ is valued on the expensive side.
  • Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 81.68% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of JAZZ to the average of the S&P500 Index (27.19), we can say JAZZ is valued slightly cheaper.
  • With a Price/Forward Earnings ratio of 7.19, the valuation of JAZZ can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, JAZZ is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, JAZZ is valued rather cheaply.
Industry RankSector Rank
PE 20.38
Fwd PE 7.19
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 87.96% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaper than 93.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.16
EV/EBITDA 11.15
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

  • JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.73
EPS Next 2Y4.5%
EPS Next 3Y6.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (2/13/2026, 8:18:31 PM)

After market: 166.31 0 (0%)

166.31

+0.02 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)02-24
Inst Owners104.02%
Inst Owner Change-0.8%
Ins Owners2.48%
Ins Owner Change-0.22%
Market Cap10.11B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts85.22
Price Target221.83 (33.38%)
Short Float %9.62%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.93%
PT rev (3m)14.73%
EPS NQ rev (1m)2.08%
EPS NQ rev (3m)5.88%
EPS NY rev (1m)1.18%
EPS NY rev (3m)54.77%
Revenue NQ rev (1m)1.02%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.37%
Valuation
Industry RankSector Rank
PE 20.38
Fwd PE 7.19
P/S 2.43
P/FCF 8.16
P/OCF 7.26
P/B 2.55
P/tB N/A
EV/EBITDA 11.15
EPS(TTM)8.16
EY4.91%
EPS(NY)23.14
Fwd EY13.91%
FCF(TTM)20.39
FCFY12.26%
OCF(TTM)22.9
OCFY13.77%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)3.73
Graham Number109.37
Profitability
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROCE 5%
ROIC 3.95%
ROICexc 5.1%
ROICexgc 55.75%
OM 10.92%
PM (TTM) N/A
GM 88.49%
FCFM 29.8%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Debt/EBITDA 3.8
Cap/Depr 22.29%
Cap/Sales 3.68%
Interest Coverage 250
Cash Conversion 122.16%
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.44
Altman-Z 1.53
F-Score5
WACC7.58%
ROIC/WACC0.52
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-60.74%
EPS Next 2Y4.5%
EPS Next 3Y6.57%
EPS Next 5Y8.62%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.8%
Revenue Next 2Y5.63%
Revenue Next 3Y6.42%
Revenue Next 5Y7.5%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-57.7%
EBIT Next 3Y5.83%
EBIT Next 5Y6.52%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%

JAZZ PHARMACEUTICALS PLC / JAZZ FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.


Can you provide the financial health for JAZZ stock?

The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -60.74% in the next year.